Friday, August 02, 2019 11:59:07 PM
The weaker the signal the higher the n or trial participants needs to be to show Stat Sig.
For instance Naloxon (Narcan) works instantly almost every time to reverse opiod overdose. Opioid overdose affects very large numbers of unfortunate victims but is certainly did not take a large trial with thousands to prove effective because of the strength of the signal.
With the Biogen drugs the signal was weak and proved to be almost nonexistant no matter how large they expanded the n.
Stubborn headed arrogance is almost always a bad idea.
A2-73 shows a fairly large signal in all preclinical work and with the human trials where the higher blood concentrations were achieved.
Find the way to consistently achieve therapeutic blood concentrations of A2-73 then as Biostockclub retorts "We got this." I believe this was the thrust and the importance of the gut biome work.
Therefore as the ALZ and PDD trials proceed it maybe that the n can be smaller and therefore a less lengthy trial than originally conceived if the signal is strong and the way to achieve the proper blood concentrations of A2-73 and is longer acting active metabolite.
Some complain wow this is taking so long. But remember as our clinical success mounts our IP patent protection must keep pace. I believe the delibrate pace of the drug development was designed not to out run the patent developments.
Some complain that Missling remains so quiet running a tight ship and divulging little information. Running silent and deep like a submarine. Same as above protecting the IP. I find it anything rather than ironic that the Anavex drug shares the same alpha numeric designation as the Polaris II. The first seaborne missile designed to fire from a submerged position. A2-73 was not the drugs first alpha numeric designation. It was renamed. Connect the dots. When Anavex ignites it almost assuredly fire from a submerged position with two stages and a powerful payload.
Chew on that! At some point AVXL will go ballistic faster than one can say Lockheed!
For instance Naloxon (Narcan) works instantly almost every time to reverse opiod overdose. Opioid overdose affects very large numbers of unfortunate victims but is certainly did not take a large trial with thousands to prove effective because of the strength of the signal.
With the Biogen drugs the signal was weak and proved to be almost nonexistant no matter how large they expanded the n.
Stubborn headed arrogance is almost always a bad idea.
A2-73 shows a fairly large signal in all preclinical work and with the human trials where the higher blood concentrations were achieved.
Find the way to consistently achieve therapeutic blood concentrations of A2-73 then as Biostockclub retorts "We got this." I believe this was the thrust and the importance of the gut biome work.
Therefore as the ALZ and PDD trials proceed it maybe that the n can be smaller and therefore a less lengthy trial than originally conceived if the signal is strong and the way to achieve the proper blood concentrations of A2-73 and is longer acting active metabolite.
Some complain wow this is taking so long. But remember as our clinical success mounts our IP patent protection must keep pace. I believe the delibrate pace of the drug development was designed not to out run the patent developments.
Some complain that Missling remains so quiet running a tight ship and divulging little information. Running silent and deep like a submarine. Same as above protecting the IP. I find it anything rather than ironic that the Anavex drug shares the same alpha numeric designation as the Polaris II. The first seaborne missile designed to fire from a submerged position. A2-73 was not the drugs first alpha numeric designation. It was renamed. Connect the dots. When Anavex ignites it almost assuredly fire from a submerged position with two stages and a powerful payload.
Chew on that! At some point AVXL will go ballistic faster than one can say Lockheed!
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
